+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 50Years +
All Genders
ID05762211

Phase IIb Study of Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Complications After Allogeneic Hematopoietic Cell Transplantation in Patients 50 Years and Older

Led by MaaT Pharma · Updated on 2024-12-27

387

Participants Needed

54

Research Sites

15 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the activity of an oral pooled fecal microbiotherapy called MaaT033 to prevent complications related to allogeneic hematopoietic cell transplantation alloHCT in patients aged 50 years and older with hematologic malignancies. This phase IIb randomized, placebo-controlled trial aims to improve overall survival by reducing transplant-related complications. The study is conducted by MaaT Pharma and includes a double-blinded design to compare the effects of the treatment against a placebo. Participants will receive either the oral pooled fecal microbiotherapy MaaT033 or a placebo in capsule form, with a dosage of three capsules per day. The study involves a reduced toxicity or reduced intensity conditioning regimen before alloHCT. The trial excludes patients receiving certain conditioning regimens or treatments, as well as those with specific medical conditions or infections. The treatment period spans the time around transplantation, with follow-up assessments planned to evaluate treatment effects. During the study, participants will be closely monitored for overall survival up to 12 months after alloHCT. Researchers will assess gut microbiota diversity restoration, incidence and severity of acute graft-versus-host disease GvHD, mortality causes, immune suppression therapy discontinuation, platelet and neutrophil engraftment times, severe infections, quality of life, and safety through adverse event monitoring. Study visits will include clinical evaluations, laboratory tests, and questionnaires to collect these data throughout the 12-month follow-up period.

CONDITIONS

Brief Title

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

Research Team

E

Emilie Plantamura, PharmD, PhD

R

Romain Collard

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here